Don't miss STAT’s coverage of new sickle cell gene therapies and the first CRISPR-based medicine

Our team of STAT reporters have covered every angle: the science, business implications, history, and hard choices they present to patients.

Log in    STAT+ ADOBE Read all of STAT's coverage of the historic approval of new sickle cell gene therapies The FDA approval last week of two gene therapies for sickle cell disease — including the first-ever medicine based on the revolutionary CRISPR gene-editing technology — was a landmark for patients with this long-neglected illness, and for medicine. In a dozen stories, STAT reporters from San Diego to Boston to New York to London have covered every angle: the science behind the treatments, the business implications, the history, and the hard choices they present to patients.   Subscribe to read all our sickle cell coverage. READ MORE STAT's CRISPR TRACKR: Follow the latest developments in genome editing A curated collection of methods, milestones, and discoveries that we at STAT believe represent a key advance in either the genome-editing technology or its application toward treating human disease. Subscribe now to access. EXPLORE TRACKR Read More Biotech In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease Biotech How sickle cell became the first disease treated by CRISPR Adam's Take After sickle-cell screwups, Bluebird Bio's only option might be a company sale Special Report New gene therapies confront many sickle cell patients with an impossible choice ALL STORIES STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us